Skip to content


  • Review
  • Open Access

Control of hypertension in the critically ill: a pathophysiological approach

  • 1, 2,
  • 3 and
  • 1Email author
Annals of Intensive Care20133:17

  • Received: 27 December 2012
  • Accepted: 14 May 2013
  • Published:


Severe acute arterial hypertension can be associated with significant morbidity and mortality. After excluding a reversible etiology, choice of therapeutic intervention should be based on evaluation of a number of factors, such as age, comorbidities, and other ongoing therapies. A rational pathophysiological approach should then be applied that integrates the effects of the drug on blood volume, vascular tone, and other determinants of cardiac output. Vasodilators, calcium channel blockers, and beta-blocking agents can all decrease arterial pressure but by totally different modes of action, which may be appropriate or contraindicated in individual patients. There is no preferred agent for all situations, although some drugs may have a more attractive profile than others, with rapid onset action, short half-life, and fewer adverse reactions. In this review, we focus on the main mechanisms underlying severe hypertension in the critically ill and how using a pathophysiological approach can help the intensivist decide on treatment options.


  • Beta-blockers
  • Calcium channel blockers
  • Cardiac output
  • Diuretics
  • Mean arterial pressure
  • Vasodilators


Arterial hypertension is a worldwide problem, affecting more than 1 billion people [1, 2]. Chronic arterial hypertension is an important cardiovascular risk factor and associated with significant morbidity and mortality in the general population [3]. Chronic hypertension also is the primary risk factor for cerebrovascular disease [4]. Acute hypertension is not uncommon in the emergency room or acute care setting [5] and can have important consequences on various organs, including the heart [6], the kidneys [7], the brain, and the lungs; associated end-organ injury has been reported in 19-81% of patients with acute severe hypertension [810]. In a recent American survey of patients with severe acute hypertension (defined as systolic arterial pressure [SAP] >180 mmHg and/or diastolic arterial pressure [DAP] >110 mmHg) requiring hospitalization, new or worsening end-organ dysfunction was observed in 59% of subjects [10]; the 90-day mortality rate was 11% [10]. More than one third of patients discharged home were rehospitalized at least once within 90 days, 29% for acute severe hypertension [11]. Interestingly, 28% of the patients had a primary neurological diagnosis and mortality rates were higher in these patients than in those without a neurological diagnosis (24% vs. 6%, p < 0.0001) [12].

According to general guidelines [1], moderate arterial hypertension is defined as a systolic arterial pressure (SAP) ≥140 mmHg or a diastolic arterial pressure (DAP) ≥90 mmHg, also known as Stage I hypertension. This degree of hypertension is rarely treated in critically ill subjects, unless it is accompanied by obvious harmful hemodynamic symptoms. Stage II hypertension (systolic arterial pressure [SAP] >160 mmHg or diastolic arterial pressure [DAP] >100 mmHg [1]) is more frequently associated with acute cardiovascular complications, including acute heart failure, intensive care unit (ICU) admission, prolonged hospital stay, and death [1, 10, 12, 13]. Values of SAP >180 mmHg and/or DAP >110 mmHg often are used to define severe hypertension [10, 14].

In discussing hypertension, it is important to differentiate some terms. Hypertensive emergencies are defined as a marked increase in arterial pressure associated with acute, life-threatening target-organ injuries (Table 1), often requiring hospitalization in an ICU for immediate pressure control. Hypertensive urgencies are not associated with imminent acute end-organ injury, so that blood pressure control can be slower, over several hours, and hospitalization may not even be necessary [1]. Because there is no consensus regarding the cutoff value of blood pressure for defining hypertensive urgencies, diagnosis should be individualized after taking into account several factors, such as age, sex, the presence of chronic hypertension (and use of antihypertensive drugs), and the presence of comorbidities. Indeed, the same degree of arterial hypertension may be associated with symptoms of acute target-organ damage in one individual or be completely asymptomatic in another. Nevertheless, in general terms, a blood pressure equal to or greater than 180/100 mmHg may require intervention [15].
Table 1

Most frequent target organs damaged during acute hypertensive crises

Organ system

Example of Injury


Acute coronary syndromes

Heart failure and pulmonary edema

Aortic dissection

Central nervous system

Stroke or transient ischemic attack

Acute encephalopathy/cerebral edema

Retinal hemorrhage


Acute renal failure

Before initiating therapy for severe acute hypertension in a critically ill patient, the presence of precipitating causes should be looked for (Table 2), because removal and/or control of these factors can prevent unnecessary treatment in many instances. In the patient with chronic hypertension, it may be wise to continue the antihypertensive medications. Unlike some other traditional reviews that cover the management of hypertensive urgencies/emergencies in specific diseases (e.g., acute aortic dissection, preeclampsia, cerebrovascular accident) [1618], we focus on the main mechanisms underlying severe hypertension in the critically ill and how a pathophysiological approach can help the practicing intensivist to manage this problem.
Table 2

Principal causes of acute systemic arterial hypertension in critically ill patients

Organ system


Decompensated essential (primary) hypertension Secondary causes

Discontinuation of antihypertensive drugs

Central Nervous System



Anxiety and stress




Withdrawal syndromes


Intracranial hypertension

Renal system

Urinary retention


Renal failure



Respiratory system

Respiratory distress – Hypoxemia, hypercapnia




Steroid administration




Cushing syndrome


Intoxication, substance abuse and overdose (cocaine, phencyclidine, amphetamines)


Pathophysiology of arterial hypertension

Regional blood flow and organ perfusion are determined by the driving pressure and by vascular autoregulation, a functional property of vessels that permits blood flow to adapt to a given level of arterial pressure and tissue metabolic demand [19, 20], thus protecting tissues against the negative effects of excessive or insufficient flow observed during hypertension and hypotension, respectively. In healthy subjects, for example, cerebral blood flow is kept relatively constant through a wide range of arterial pressures (usually a mean arterial pressure [MAP] from 60-120 mmHg) [5]. Various mechanisms are involved in vessel autoregulation, including activation of the autonomic system and local production of vasoactive substances, such as angiotensin II, endothelin, prostanoids, nitric oxide (NO), adenosine, reactive oxygen species (ROS), and lactate [21, 22]. Endothelial dysfunction also may contribute to the development of systemic hypertension. In this respect, preeclampsia, a disease model of systemic endothelial dysfunction, and some recent chemotherapy drugs that inhibit vascular endothelial growth factor (VEGF), share similar physiological mechanisms for the genesis of hypertension by inhibiting VEGF, reducing the production of NO and increasing systemic vascular resistance (SVR) [23].

When faced with a patient with severe acute hypertension, one needs to keep in mind the two determinants of arterial pressure [24]:
where CO is the cardiac output. SVR essentially represents the degree of vascular tone. Because CO is the product of the heart rate (HR) and the stroke volume (SV), we can write:

The vascular tone (SVR) is mainly determined by the degree of constriction of precapillary and small arterioles and, to a lesser degree, by the blood viscosity (k). The vascular tone is an important determinant of ventricular afterload. Cardiac output is determined by heart rate, afterload, myocardial contractility, and preload. Preload is largely determined by the volume status, which is represented by the central venous pressure (CVP), pulmonary artery occlusion pressure (PAOP), or inferior vena cava diameter in the clinical setting. Cardiac contractility is difficult to assess at the bedside but can be indirectly appreciated by the assessment of the ventricular stroke work index (basically derived from the product of stroke index and MAP) and the ejection fraction obtained by echocardiography [25]. Increased myocardial contractility can, in principle, contribute to the development of hypertension, although this would only be observed in hyperadrenergic conditions.

Combining all these aspects, a final equation for arterial pressure can be derived:
MAP = HR × preload x myocardial contractility × SVR

Physicians will be able to manage most cases of severe hypertension in critically ill patients by associating these physiological principles with knowledge of the pharmacological properties of the available antihypertensive drugs.

Treatment options for severe acute hypertension inthe ICU

In patients with chronically uncontrolled hypertension, the circulation in vital organs, such as the brain, heart, and kidney, adapts, resulting in arteriolar hypertrophy. These patients are prone to develop organ ischemia when blood pressure is rapidly reduced, even to levels considered as relatively high in normotensive patients [5, 26], and one should be particularly cautious when controlling arterial pressure in such individuals. As a general rule for the treatment of hypertensive emergencies, one should not try to reduce the MAP by more than 20% (or diastolic blood pressure by 10-15% or to approximately 110 mmHg) during the first hour, except in acute aortic dissection where this goal should be achieved within 10 min [27].

There are a large number of therapeutic options for severe hypertension. We will restrict our discussion to the agents most frequently used in ICU patients (Tables 3 and 4).
Table 3

Main cardiovascular effects of the different antihypertensive drugs


Heart rate

Myocardial contractility


Systemic vascular resistance






_ _





_ _

_ _





_ _ _

ACE inhibitors and AT1 receptor blockers




_ _ _

Calcium channel blockers











+ + +







_ _





_ _ _

_ _



β-blockers with intrinsic





sympathomimetic activity



0/ _



_ _ _




_ _

_ _ _




_ _ _

+ +


_ _



_ _


0/ _

0/ _

0/ +

_ _

0, no effect; - Slight negative effect; -- moderate negative effect; --- strong negative effect.

+ Slight positive effect; + + moderate positive effect; + + + strong positive effect.

ACE angiotensin-converting enzyme, AT1 angiotensin II subtype 1.

Table 4

Doses, pharmacokinetics, and pharmacodynamics of the intravenous antihypertensive agents most frequently used in intensive care units


Intravenous dose

Onset/peak of action

Half-life/duration of action


Main side effects

Main clinical indications

Sympatholytic drugs




Propranolol (β1- and β2-receptor blocker)

1-3 mg every 2–5 min (over 1–30 min)

Onset: 5 min

Half-life: 3–5 h

Metabolism: hepatic CYP450

Hypotension, heart failure, heart block, dizziness, fatigue, confusion, depression, bronchospasm, Raynaud´s phenomenon, diarrhea, pruritus, rash

Cardiac ischemic syndromes with arterial hypertension and normal heart function. Avoid in pheochromocytoma crises

Max dose: 5 mg


Duration: 6–12 h

Excretion: urine (96-99%)

Infusion: not recommended


Metoprolol (selective β1-receptor blocker)

5 mg every 3 min (over 1–30 min)

Onset: 5–10 min

Half-life: 3–7 h

Metabolism: hepatic CYP2D6

Hypotension, heart failure, heart block, dizziness, fatigue, depression, bronchospasm, diarrhea, pruritus, rash

Cardiac ischemic syndromes with arterial hypertension and normal heart function

Max dose: 15 mg


Duration: 5–8 h

Excretion: urine (5-10% unchanged)

Infusion: not recommended


Labetalol (α1, β1, and β2-receptor blocker)

Bolus: 20–80 mg every 10 min. Max dose: 300 mg

Onset: 5–10 min

Half-life: 6 h

Metabolism: hepatic glucuronide conjugation

Nausea, scalp tingling, bronchospasm, dizziness, heart block, orthostatic hypotension

Most hypertensive emergencies, good for hypertension in neurocritically ill patients and pregnancy; caution in heart failure

Infusion: 0.5-2.0 mg/min

Peak: 5–15 min

Duration: 3–18 h

Excretion: urine 50% (<5% unchanged), feces 50%

Esmolol (selective β1-receptor blocker)

Bolus: 500 μ g/Kg (over 1 min)

Onset: 1–2 min

Half-life: 9 min

Metabolism: plasma esterases

Arterial hypotension, bronchospasm, heart block, heart failure

Hypertensive emergencies with normal or high cardiac output, and aortic dissection in particular. Contraindicated in pheochromocytoma crisis

Max dose: 300 μg/Kg/min

Peak: 6–10 min

Duration: 10–30 min

Excretion: urine 70-90% (<1% unchanged)

Infusion: 50–300 μg/Kg/min


α-Adrenergic antagonists


Phentolamine (peripheral α-receptor antagonist)

Bolus: 5–20 mg

Onset: 1–2 min

Half-life: 19 min

Metabolism: hepatic

Tachycardia, flushing, headache, orthostatic hypotension, dizziness, nasal congestion, pulmonary hypertension

Hypertensive emergencies associated with excessive catecholamine levels

Max dose: 15 mg

Peak: 10–20 min

Duration: 15–30 min

Excretion: urine (10% unchanged)

Infusion: not recommended


Urapidil (peripheral α1-receptor antagonist and central serotonin antagonist)

Bolus: 12.5-25 mg

Onset: 3–5 min

Half-life: 2–4.8 h

Metabolism: hepatic

Headache, hypotension, dizziness

Hypertensive emergencies in postoperative and pregnant patients


Max dose: 50 mg

Peak: 0.5-6 h

Duration: 4–6 h

Excretion: urine (15-20% unchanged), feces 10%


Infusion: 5–40 mg/h


Centrally acting agents


Clonidine (central α2 receptor agonist)

Bolus: not recommended

Onset: 5–10 min

Half-life: 12 h

Metabolism: Hepatic CYP450

Eye and mouth dryness, sedation, erectile dysfunction, orthostatic hypotension, bradycardia, drowsiness.

Hypertensive emergencies, particularly in the context of withdrawal syndrome and pain

Max dose: 7.2 μg/min (or 450 μg/2 h)

Peak: 2–4 h

Duration: 6–10 h

Excretion: Urine (50% unchanged), feces/bile 20%

Infusion: 1.2-7.2 μg/min


Methyldopa (central α2 receptor agonist)

250-1000 mg every 6-8h

Onset: >1 h

Half-life: 2 h

Metabolism: Hepatic CYP450 and central adrenergic neurons

Peripheral edema, fever, depression, sedation, dry mouth, bradycardia, hepatitis, hemolytic anemia, lupus-like syndrome

Hypertensive emergencies, particularly in pregnant patients. Use limited by adverse effects

Max dose: 1000 mg every 6h

Peak: 6–8 h

Duration: 12–24 h

Excretion: urine (85% metabolites), feces

Infusion: not recommended


Dexmedetomidine (central α2receptor agonist)

Bolus: 1 μg/Kg/min over 10 min (not necessary in sedated patients)

Onset: 6–15 min

Half-life: 2–2.5 h

Metabolism: hepatic

Hypotension, bradycardia, fever, nausea, vomiting, hypoxia, anemia

Hypertensive urgencies associated with hyperactive delirium or withdrawal syndrome

Max dose: 1.5 μg/Kg/h

Peak: 1 h

Duration: 4 h

Excretion: urine (metabolites)

Infusion: 0.2-0.7 μg/Kg/h


Calcium channel blockers



Bolus: not recommended

Onset: 5–10 min

Half-life: 2–4 h

Metabolism: hepatic CYP3A4

Tachycardia, headache, flushing, peripheral edema, angina, nausea, AV block, dizziness

Most hypertensive emergencies; caution in heart failure

Max dose: 30 mg/h

Peak: 30 min

Duration: 4–6 h

Excretion: urine 60% (<1% unchanged), feces 35%

Infusion: 5–15 mg/h



Bolus: not recommended

Onset: 1–2 min

Half-life: 1–15 min

Metabolism: plasma and tissue esterases

Atrial fibrillation, nausea, fever, insomnia, headache, acute renal failure

All hypertensive emergencies, particularly postoperative hypertension

Max dose: 32 mg/h

Peak: 3 min

Duration: 5–15 min

Excretion: urine 63-74%, feces 7-22%

Infusion: 1–2 mg/h



Bolus: 0.25 mg/Kg (over 2 min)

Onset: 2–7 min

Half-life: 3.4 h

Metabolism: hepatic CYP3A4

Bradycardia, AV block, hypotension, cardiac failure, peripheral edema, headache, constipation, hepatic toxicity

Hypertensive emergencies associated with normal heart function and tachyarrhythmia

Max dose: 15 mg/h

Peak: 7–10 min

Duration:30 min-10 h (median 7 h)

Excretion: bile, urine (2-4% unchanged)

Infusion: 5–15 mg/h (≤24 h)


ACE inhibitor



Bolus: 1.25-5 mg every 6 h

Onset: 15–30 min

Half-life: 11 h

Metabolism: hepatic biotransformation

Hypotension, headache, worsening of renal function, hyperkalemia, angioedema, cough, agranulocytosis

Hypertensive emergencies associated with left ventricular dysfunction; caution in hypovolemia

Max dose: 5 mg every 6 h

Peak: 3–4.5 h

Duration: 6–12 h

Excretion: urine (60-80%)

Infusion: not recommended


Arterial vasodilators


Hydralazine (arteriolar vasodilator)

Bolus: 10–20 mg every 4–6 h

Onset: 5–20 min

Half-life: 2–8 h

Metabolism: Hepatic acetylation

Hypotension, tachycardia, headache, facial flushing, angina pectoris, vomiting, paradoxical hypertension, lupus-like syndrome

Hypertensive emergencies, especially severe hypertension in pregnancy

Max dose: 40 mg per dose

Peak: 30–60 min

Duration: 1–8 h

Excretion: urine 52-90% (14% unchanged), feces 10%

Infusion: not recommended


Fenoldopam (selective dopamine type 1-receptor agonist)

Bolus: not recommended

Onset: 5–10 min

Half-life: 5 min

Metabolism: Hepatic methylation

Hypotension, tachycardia, headache, nausea, facial flushing, angina, ST-T wave changes, elevated intraocular pressure

Hypertensive emergencies, especially severe hypertension in patients with acute renal failure

Max dose: 1.6 μg/Kg/min

Peak: 15 min

Duration:30–60 min

Excretion: urine 90%, feces 10%.

Infusion: 0.05-1.6 μg/Kg/min


Mixed arterial/venous vasodilators


Nitroprusside (nitric oxide donor)

Bolus: not recommended

Onset: 1–2 min

Half-life: <10 min (nitroprusside), 3 days (thiocyanate)

Metabolism: erythrocytes, hepatic methylation

Hypotension, tachycardia, headache, cyanide and thiocyanide intoxication, nausea, flushing, vomiting, muscle spasm, pulmonary shunt

Hypertensive emergencies, especially aortic dissection. Caution in renal and hepatic failure

Max dose: 10 μg/Kg/min (<1 h)

Peak: 15 min


Excretion: urine

Infusion: 0.25-4 μg/Kg/min


Duration: 1–10 min


Nitroglycerin (nitric oxide donor with predominant venular action)

Bolus: not recommended

Onset: 2–5 min

Half-life: 1–3 min

Metabolism: erythrocytes, hepatic, vessel wall

Hypotension, headache, dizziness, vomiting, tachyphylaxis, methemoglobinemia

Hypertensive emergencies, especially those associated with acute coronary syndrome, volume overload, or pulmonary edema

Max dose: 300 μg/min

Peak: 5 min

Duration: 5–10 min

Excretion: urine

Infusion: 5–300 μg/min




Furosemide (inhibits reabsorption of Na/Cl in the ascending loop of Henle)

Bolus: 20–40 mg

Onset: 5 min

Half-life: 30–60 min

Metabolism: hepatic

Hypokalemia, hypovolemia, hypotension, metabolic alkalosis, ototoxicity, thrombocytopenia, pancreatitis, interstitial nephritis, hyperglycemia, hyperuricemia

Hypertensive emergencies, especially those associated hypervolemia and/or heart failure

Max dose: 200 mg/dose or 160 mg/h

Peak: 1–2 h

Duration: 2 h

Excretion: urine 88%, bile/feces 12%.

Infusion: 10–40 mg/h


Bumetanide (inhibits reabsorption of Na/Cl in the ascending loop of Henle)

Bolus: 0.5-1 mg/dose up to 2 times/day

Onset: 2–3 min

Half-life: 1–1.5 h

Metabolism: hepatic

Hypokalemia, hypovolemia, hypotension, metabolic alkalosis, ototoxicity, thrombocytopenia, pancreatitis, interstitial nephritis, hyperglycemia, hyperuricemia

Hypertensive emergencies, especially those associated with hypervolemia and/or heart failure

Max dose: 10 mg/day

Peak: 1–4 h

Duration:4–6 h

Excretion: urine 81%, bile 2%


Infusion: 0.5-2 mg/h


ACE angiotensin-converting enzyme.



Although described as having antihypertensive effects, nitroglycerin causes weak direct arterial vasodilation, which is observed only with high doses (>60 μg/min intravenously) [28]. Nitroglycerin has a more profound venodilating than arteriolar effect. In the presence of hypovolemia, it may cause a decrease in venous return and CO; in these conditions, reflex tachycardia is common [27]. Nitroglycerin is indicated in severe hypertension associated with volume overload and pulmonary edema. Nitroglycerin promotes coronary vasodilation without steal syndrome [29], so that it may be used at low doses (≤60 μg/min) as an adjunct to other intravenous antihypertensive agents in patients with acute coronary syndromes [14]. Nitroglycerin (as other vasodilators) may increase pulmonary shunt and aggravate systemic hypoxemia by inhibiting pulmonary hypoxic vasoconstriction.


Sodium nitroprusside is a potent and short-acting purely vasodilatory agent, causing both arterial and venous vasodilation, thus reducing pre- and afterload. The rapid onset of action and short half-life mean that this drug is easily titrated, but because of its potency, speed of action, and risk of tachyphylaxis, intraarterial blood pressure monitoring is recommended [15]. The major unwanted effect if used at high doses for prolonged periods (>8 hours) is the generation of the toxic metabolites, cyanide and thiocyanide, which accumulate more rapidly in the presence of renal and hepatic failures. Nitroprusside infusion also may alter gas exchange by aggravating pulmonary shunt, increase intracranial pressure by inducing vasodilation, induce coronary steal syndrome by nonselective coronary vasodilation, and may be associated with spinal ischemia and paralysis during thoracic aortic surgery [30]. Nitroprusside is now rarely used or recommended as a first-line agent; if used, limited doses and infusion durations are preferred [15, 27].


Hydralazine is a direct arterial vasodilator without significant effects on the venous system. Its mechanisms of action are complex and involve inhibition of calcium influx into vascular smooth muscle cells, either by cell membrane hyperpolarization or by induction of cGMP [31, 32]. Hydralazine increases heart rate and has a slight positive inotropic effect. Hydralazine is indicated for severe hypertension associated with increased SVR, especially in the presence of bradycardia. However, hydralazine causes a reflex increase in sympathetic tone and can worsen myocardial oxygen consumption, so should be used with caution in patients with known heart disease (e.g., heart failure, coronary artery disease, or valvular dysfunction). Fluid retention resulting from activation of the sympathetic and renin-angiotensin systems following peripheral vasodilation can be managed by adding diuretic drugs if needed. Hydralazine can have prolonged antihypertensive effects and dosage titration can be difficult [33].

Hydralazine has been used for a long-time as a first-line agent for pregnancy-induced hypertensive disorders, but there is evidence suggesting that parenteral hydralazine may be associated with more adverse outcomes, including maternal hypotension, placental abruption, fetal heart rate abnormalities, Cesarean section, stillbirth, and fetal suffering compared with labetalol and calcium channel blockers [34, 35].


As a specific dopamine type-1 receptor agonist, fenoldopam increases renal blood flow, stimulates natriuresis and urinary output, and may improve renal function, so that it may be suitable for the treatment of severe hypertension in patients with renal failure [36]. Fenoldopam has a rapid onset of action, a relatively short half-life, no rebound effect, and no negative effects on cardiac function [37, 38], although it also may be associated with mild tolerance and hypokalemia after prolonged infusions. Anaphylactic reactions have been reported in patients with known sulfite sensitivity because fenoldopam contains a metabisulfite molecule. It can increase intraocular pressure and thus also is contraindicated in patients with glaucoma. Fenoldopam is not currently available in many countries.


Enalaprilat is an intravenous angiotensin-converting enzyme (ACE) inhibitor that reduces peripheral arterial vasoconstriction caused by angiotensin II. Its final antihypertensive effect is highly dependent on the patient’s volume status and plasma renin activity [39]. Hence, in normo- or hypervolemic patients without increased angiotensin II levels, enalaprilat will not cause major hypotension. Conversely, in hypovolemic subjects with high angiotensin II levels, the antihypertensive effect can be significant [39]. Enalaprilat may be considered in severe hypertension associated with heart failure. Because of its unpredictable effects, long half-life, and risk of excessive hypotensive response (especially in hypovolemic hyperreninemic patients), it is not considered as a first-line agent for the treatment of acute hypertension. Enalaprilat is contraindicated in pregnancy [40].

Calcium channel blockers

These drugs inhibit calcium influx through voltage-sensitive L-type calcium channels in vascular smooth muscle cells inducing arteriolar vasodilation and reducing SVR. They are divided into two pharmacological classes: dihydropyridines and nondihydropyridine derivatives. The dihydropyridines (e.g., nifedipine, nicardipine, amlodipine) are the largest class, and members have greater vasodilatory potency and less negative chronotropic activity, making them relatively safe for patients with hypertension. However, they can be potentially hazardous in patients with severe heart failure because of the calcium entry blocking effects. Two agents, nicardipine and clevidipine, are available for continuous intravenous infusion for the management of arterial hypertension. Nicardipine is a second-generation dihydropyridine with high hydrosolubility, and short onset but a relatively long duration of action. Its dosage is weight-independent, easily titrated, and it promotes cerebral and coronary vasodilation [41]. Nicardipine has been used for the treatment of severe hypertension, particularly in the perioperative period [42, 43], and has recently been shown to be superior to labetalol in treating acute severe hypertension in emergency department patients [44], including those with end-organ damage [45], and also in critically ill patients [46].

Clevidipine, a third-generation dihydropyridine, is an ultrashort acting agent. It is metabolized by plasma esterases and has few drug interactions, making it useful for severe hypertension in critically ill patients, particularly those with renal and/or hepatic failure [47, 48]. Clevidipine exerts vascular-selective, arterial specific vasodilation, without negative effects on cardiac function, because it does not significantly affect preload and induces minimal reflex tachycardia [9, 49]. Clevidipine has been shown to be more effective than other vasodilators, such as sodium nitroprusside and nitroglycerin, in the control of acute hypertension during the perioperative period of cardiac surgery [49, 50]. It also has been reported to be safe and effective in the management of acute severe hypertension in patients with acute heart failure and renal dysfunction [51, 52]. Because it is a fairly new agent, it is relatively expensive compared with other agents.

The nondihydropyridine derivatives, which include diltiazem and verapamil, are less potent vasodilators but with significant negative chronotropic activity, making them less commonly used as antihypertensive drugs.

Beta-blocking agents

β-adrenergic receptor antagonists (β-blockers) inhibit the action of norepinephrine, epinephrine, and other sympathomimetic drugs acting on β receptors. As a general rule, the greater the degree of β stimulation that occurs at a given site, the greater the observed effect of β-blockers.

β-blocking agents primarily decrease blood pressure by a reduction in cardiac output (through a reduction in both contractility and heart rate). They also can reduce renin release by the juxtaglomerular cells, resulting in less angiotensin II formation, less generation of NO [53], suppression of the central nervous sympathetic outflow, alteration of baroreceptor sensitivity, and attenuation of the peripheral pressor response to catecholamines [54]. β-blockers reduce the risk of cardiovascular disease and are of particular interest for patients with ischemic cardiomyopathy, because they reduce myocardial oxygen consumption and increase coronary blood flow toward ischemic regions [55]. β-blocking agents should not be used in isolation in catecholamine-induced severe hypertension seen with pheochromocytoma or stimulant intoxication, because the unopposed peripheral α-effect could further increase blood pressure [17, 56]. Obviously, β-blocking agents must be avoided in situations where a reduction in oxygen delivery could be problematic.

Various β-blockers are available, with different degrees of specificity for β1-receptor antagonism, intrinsic sympathomimetic activity, membrane-stabilizing properties, capacity to induce vasodilation, lipid solubility, half-life, onset of action, and routes of administration [57]. β-blocker agents are classified as non-subtype receptor selective (first generation), β1-receptor selective (second generation), and antagonists with additional cardiovascular actions (third generation). Some examples are presented in Table 4. Of particular interest is esmolol, an ultrashort acting β1-blocker, which is rapidly metabolized by plasma esterases (safe in renal and hepatic failure) and has a short half-life. Esmolol is a good option for the treatment of severe hypertension, because it can be easily titrated and discontinued in high-risk patients or if poorly tolerated, e.g., if heart failure, atrioventricular block or bronchospasm develop [58, 59]. Labetalol, an example of a third generation β-blocker, competitively inhibits α1 and β receptors, resulting in a decrease in blood pressure by both vasodilation and reduction of the sympathetic stimulation of the heart. Labetalol infusion is useful in the management of hypertensive crises, particularly in pregnancy-induced hypertensive emergencies because of its negligible lipid solubility and placental transfer [35], but should be used with caution in patients with hepatic failure [60].

Alpha-blocking agents

Phentolamine (peripheral α-receptor antagonist)

This peripheral α-adrenergic receptor blocker has limited use in the management of severe hypertension because of the risk of severe hypotension and other adverse effects. Phentolamine is mainly indicated for the treatment of hypertensive emergencies associated with excessive circulating catecholamines, such as in pheochromocytoma crisis or cocaine intoxication [61, 62]. It is no longer available in many countries.


This drug combines selective postsynaptic α1-adrenergic antagonist activity with central antagonism of serotonin receptors, which gives it a potent vasodilatory effect reducing both pre- and afterload, as well as causing pulmonary and renal vasodilation, without any significant effect on cardiac function. It is relatively safe because it does not affect coronary and cerebral blood flow. Urapidil has a rapid onset of action, with good efficacy. It has been used for the treatment of severe hypertension in the postoperative period and pregnancy but is contraindicated in patients with aortic isthmus stenosis, major arteriovenous shunt, and during lactation [63].


Diuretic drugs provoke inhibition of sodium chloride reabsorption at different sites in the nephron. Because diuretics reduce sodium and water load, and consequently volemia, they are particularly useful for the treatment of hypertension associated with hypervolemic and edematous states. For blood pressure control, loop of Henle diuretics (furosemide and bumetanide) are preferred for their rapid onset of action and high potency. Furosemide may have a direct venodilating effect, although this is debated [64].

Diuretics should be used with caution in acute hypertension, because these patients are often hypovolemic. Use of ACE inhibitors or other vasodilators may abolish the increment of SVR induced by furosemide [65], and the ACE inhibitor/diuretic association can be an interesting combination for the long-term treatment of hypertensive patients.

Centrally acting antihypertensives


Clonidine is a centrally acting α2-adrenergic agonist. It is more frequently used via the oral route, but an intravenous formulation is available in some countries. It can be used as an alternative to β−blocking agents, because it associates some vasodilating properties with negative chronotropic effects and is not contraindicated in heart block or bronchospasm. Clonidine is particularly indicated in severe hypertension associated with pain, anxiety, or withdrawal syndromes, because it has sedative and analgesic-sparing properties [66]. However, it should be avoided in patients with a reduced conscious level. Clonidine should be discontinued gradually because of possible rebound hypertension [67]. In addition, intravenous clonidine can induce a transient increase in arterial pressure so that close monitoring is necessary [68]. Clonidine also can be associated with unpleasant effects, including dry eye and mouth, excessive sedation, and postural hypotension. The availability of other, safer drugs means that clonidine is not used as a first-line agent for severe acute hypertension [69].


Although primarily a sedative agent, dexmedetomidine is a selective α2-adrenergic agent with rapid onset of action and easy titration, which could contribute to the control of hypertension in withdrawal syndromes [70].


Initially used in the treatment of eclampsia, intravenous methyldopa is no longer widely used because of its adverse effects. An oral formulation is still available, but the availability of newer drugs with shorter half-lives and fewer adverse effects has limited its use.

Choosing the most appropriate antihypertensive treatment in the ICU

There is no ideal drug for the treatment of severe acute hypertension in all patients and it is only by recognizing the underlying pathophysiological process and understanding the risk-benefit ratio of each medication that the intensivist will be able to choose the best therapy for the individual patient. A recent report from the European registry for Studying the Treatment of Acute hyperTension (Euro-STAT), including 761 patients treated with intravenous antihypertensive agents in the emergency department, perioperative unit, or ICU, reported that nitroglycerin was the most commonly used antihypertensive treatment (40% of patients), followed by urapidil (21%), clonidine (16%), and furosemide (8%) [8]. However, in a United States registry of 1,588 critically ill patients with acute severe hypertension treated with intravenous therapy, β-blockers were the most frequently used antihypertensive agent (labetalol 32% and metoprolol 17%), followed by nitroglycerin (15%), hydralazine (15%), nicardipine (8%), and sodium nitroprusside (5%) [10]. Interestingly, most of the patients in this survey (64%) required more than one drug for blood pressure control. These regional differences are due to several factors, including marketing influences.

Antihypertensive agents for acutely ill patients should optimally have a rapid onset of action, a short half-life enabling easy titration, and no adverse effects. For the patient with less severe hypertension who will need prolonged treatment, a long-acting antihypertensive may be started at the same time as the short-acting drug.

Some important clinical issues must be considered before starting therapy. First, a careful search and correction of precipitating factors should be made (Table 2). Second, major neurological problems should be excluded. In the presence of intracranial hypertension, every attempt should be made first to control intracranial hypertension before starting antihypertensive drugs, because a reduction in cerebral perfusion pressure (the difference between MAP and intracranial pressure) can precipitate or worsen brain injury. In the presence of intracranial hypertension, vasodilators are not the best agents, because an increase in intracranial blood volume can further increase intracranial pressure. In these circumstances, β-blocking agents are a good option. Third, if drug therapy is needed, it must be based on underlying pathophysiological considerations. For this purpose, one should consider the most important components of acute hypertension: blood volume, heart rate, cardiac function, and vascular tone. Some comorbidities also must be considered: the best example is the cautious use of β-blockers in patients with severe chronic obstructive pulmonary disease or A-V block. Fourth, in all cases, an abrupt reduction in blood pressure must be avoided. In general, the reduction in MAP should not exceed 15-20% in the first 30 to 60 min [27]. A notable exception is the presence of acute aortic dissection for which faster (within 15 min) and greater pressure control may be required [71].

The first question that should then be asked is whether or not cardiac output is increased. Maintenance of a high arterial pressure associated with a hyperkinetic state is only possible when cardiac function is well preserved, because cardiac work (essentially the product of arterial pressure and stroke volume) must be unnecessarily increased. These states are observed when there is hypervolemia and/or increased sympathetic tone. In the presence of hypervolemia, diuretics are the preferred drugs.

In the presence of increased adrenergic tone, tachycardia is typically present. Withdrawal syndromes are an example of this category. β-blocking agents are good options for the control of hypertension associated with hyperadrenergic states. If acute reduction in cardiac output is of concern, a dihydropyridine calcium channel blocker (e.g., nicardipine, clevidipine) may be preferred, because these agents have fewer negative effects on the heart rate and myocardial contractility. These agents provide an interesting option for the treatment of postoperative hypertension [28]. If a vasodilating effect is best avoided (e.g., in the presence of increased intracranial hypertension), clonidine may be a good alternative to β-blocking agents.

If cardiac output is not increased much, then the increase in arterial pressure is primarily the result of increased vascular tone. In these conditions, vasodilators are a logical choice. Venous vasodilators (nitroglycerin) are particularly indicated in the presence of pulmonary edema (in association with diuretics). Nitroprusside remains a valuable agent on a short-term basis in the presence of severe heart failure (because it has no negative inotropic affects). Its balanced effects on the arterial and venous sides of the vasculature make it more effective than nitroglycerin. Its main advantage is its very short half-life, allowing easy titration. Urapidil also may be considered where it is available.

A proposed treatment strategy based on a pathophysiological approach is presented in Figure 1.
Figure 1
Figure 1

Pathophysiological approach to the treatment of acute systemic arterial hypertension in critically ill patients based on the main determinants of the mean arterial pressure (MAP). HR, heart rate; SVR, systemic vascular resistance; ALI, acute lung injury; ARDS, acute respiratory distress syndrome; COPD, chronic obstructive pulmonary disease.


Severe acute hypertension is an interesting hemodynamic challenge. Whereas fluid refractory hypotension is generally treated with a single agent (a vasopressor), hypertension can be treated with a large array of drugs. After recognition and removal of precipitating factors, drug therapy should be initiated and guided by a pathophysiological approach, which consists of the identification of the principal determinants of arterial pressure and a basic pharmacological knowledge of the most frequently used antihypertensive agents. This strategy permits rational management of individual cases and will help to reduce undesirable side effects resulting from inadequate or inappropriate therapy.

Author contributions

DRS and JLV drafted the manuscript. DRS, ES, and JLV revised the initial draft. All authors read and approved the final manuscript.


Authors’ Affiliations

Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles, route de Lennik 808, Brussels, 1070, Belgium
Dept of Internal Medicine, Universidade Federal do Rio de Janeiro, Rua Professor Rodolpho Paulo Rocco, 255 Sala 4A, Rio de Janeiro, 12-21941-913, Brazil
Intensive Care Unit, Albert Einstein Hospital, Sao Paulo, Brazil


  1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289: 2560–2572. 10.1001/jama.289.19.2560View ArticlePubMedGoogle Scholar
  2. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell C, Roger V, Sorlie P, Steinberger J, Thom T, Wilson M, Hong Y: Heart disease and stroke statistics–2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008, 117: e25-e146.View ArticlePubMedGoogle Scholar
  3. Danaei G, Ding EL, Mozaffarian D, Taylor B, Rehm J, Murray CJ, Ezzati M: The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med 2009, 6: e1000058. 10.1371/journal.pmed.1000058PubMed CentralView ArticlePubMedGoogle Scholar
  4. Owens WB: Blood pressure control in acute cerebrovascular disease. J Clin Hypertens (Greenwich) 2011, 13: 205–211. 10.1111/j.1751-7176.2010.00394.xView ArticleGoogle Scholar
  5. Shafi T: Hypertensive urgencies and emergencies. Ethn Dis 2004, 14: S2-S7.PubMedGoogle Scholar
  6. Styron JF, Jois-Bilowich P, Starling R, Hobbs RE, Kontos MC, Pang PS, Peacock WF: Initial emergency department systolic blood pressure predicts left ventricular systolic function in acute decompensated heart failure. Congest Heart Fail 2009, 15: 9–13. 10.1111/j.1751-7133.2008.00047.xView ArticlePubMedGoogle Scholar
  7. Szczech LA, Granger CB, Dasta JF, Amin A, Peacock WF, McCullough PA, Devlin JW, Weir MR, Katz JN, Anderson FA Jr, Wyman A, Varon J: Acute kidney injury and cardiovascular outcomes in acute severe hypertension. Circulation 2010, 121: 2183–2191. 10.1161/CIRCULATIONAHA.109.896597View ArticlePubMedGoogle Scholar
  8. Vuylsteke A, Vincent JL, de La Payen GD, Anderson FA, Emery L, Wyman A, Rushton-Smith S, Gore JM: Characteristics, practice patterns, and outcomes in patients with acute hypertension: European registry for Studying the Treatment of Acute hyperTension (Euro-STAT). Crit Care 2011, 15: R271. 10.1186/cc10551PubMed CentralView ArticlePubMedGoogle Scholar
  9. Pollack CV, Varon J, Garrison NA, Ebrahimi R, Dunbar L, Peacock WF: Clevidipine, an intravenous dihydropyridine calcium channel blocker, is safe and effective for the treatment of patients with acute severe hypertension. Ann Emerg Med 2009, 53: 329–338. 10.1016/j.annemergmed.2008.04.025View ArticlePubMedGoogle Scholar
  10. Katz JN, Gore JM, Amin A, Anderson FA, Dasta JF, Ferguson JJ, Kleinschmidt K, Mayer SA, Multz AS, Peacock WF, Peterson E, Pollack C, Sung GY, Shorr A, Varon J, Wyman A, Emery LA, Granger CB: Practice patterns, outcomes, and end-organ dysfunction for patients with acute severe hypertension: the Studying the Treatment of Acute hyperTension (STAT) registry. Am Heart J 2009, 158: 599–606. 10.1016/j.ahj.2009.07.020View ArticlePubMedGoogle Scholar
  11. Gore JM, Peterson E, Amin A, Anderson FA Jr, Dasta JF, Levy PD, O'Neil BJ, Sung GY, Varon J, Wyman A, Granger CB: Predictors of 90-day readmission among patients with acute severe hypertension. The cross-sectional observational Studying the Treatment of Acute hyperTension (STAT) study. Am Heart J 2010, 160: 521–527. 10.1016/j.ahj.2010.06.032View ArticlePubMedGoogle Scholar
  12. Mayer SA, Kurtz P, Wyman A, Sung GY, Multz AS, Varon J, Granger CB, Kleinschmidt K, Lapointe M, Peacock WF, Katz JN, Gore JM, O'Neil B, Anderson FA: Clinical practices, complications, and mortality in neurological patients with acute severe hypertension: the Studying the Treatment of Acute hyperTension registry. Crit Care Med 2011, 39: 2330–2336. 10.1097/CCM.0b013e3182227238View ArticlePubMedGoogle Scholar
  13. Peacock F, Amin A, Granger CB, Pollack CV Jr, Levy P, Nowak R, Kleinschmidt K, Varon J, Wyman A, Gore JM: Hypertensive heart failure: patient characteristics, treatment, and outcomes. Am J Emerg Med 2011, 29: 855–862. 10.1016/j.ajem.2010.03.022View ArticlePubMedGoogle Scholar
  14. Varon J, Marik PE: Clinical review: the management of hypertensive crises. Crit Care 2003, 7: 374–384. 10.1186/cc2351PubMed CentralView ArticlePubMedGoogle Scholar
  15. Marik PE, Varon J: Hypertensive crises: challenges and management. Chest 2007, 131: 1949–1962. 10.1378/chest.06-2490View ArticlePubMedGoogle Scholar
  16. Varon J: The diagnosis and treatment of hypertensive crises. Postgrad Med 2009, 121: 5–13.View ArticlePubMedGoogle Scholar
  17. Papadopoulos DP, Mourouzis I, Thomopoulos C, Makris T, Papademetriou V: Hypertension crisis. Blood Press 2010, 19: 328–336. 10.3109/08037051.2010.488052View ArticlePubMedGoogle Scholar
  18. Johnson W, Nguyen ML, Patel R: Hypertension crisis in the emergency department. Cardiol Clin 2012, 30: 533–543. 10.1016/j.ccl.2012.07.011View ArticlePubMedGoogle Scholar
  19. Camici PG, Crea F: Coronary microvascular dysfunction. N Engl J Med 2007, 356: 830–840. 10.1056/NEJMra061889View ArticlePubMedGoogle Scholar
  20. Ince C: The microcirculation is the motor of sepsis. Crit Care 2005,9(Suppl 4):S13-S19. 10.1186/cc3753PubMed CentralView ArticlePubMedGoogle Scholar
  21. Cohen JD: Overview of physiology, vascular biology, and mechanisms of hypertension. J Manag Care Pharm 2007, 13: S6-S8.PubMedGoogle Scholar
  22. Liu Y, Gutterman DD: Vascular control in humans: focus on the coronary microcirculation. Basic Res Cardiol 2009, 104: 211–227. 10.1007/s00395-009-0775-yPubMed CentralView ArticlePubMedGoogle Scholar
  23. Robinson ES, Khankin EV, Karumanchi SA, Humphreys BD: Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. Semin Nephrol 2010, 30: 591–601. 10.1016/j.semnephrol.2010.09.007PubMed CentralView ArticlePubMedGoogle Scholar
  24. Pinsky MR: Hemodynamic evaluation and monitoring in the ICU. Chest 2007, 132: 2020–2029. 10.1378/chest.07-0073View ArticlePubMedGoogle Scholar
  25. Tibby SM, Murdoch IA: Monitoring cardiac function in intensive care. Arch Dis Child 2003, 88: 46–52. 10.1136/adc.88.1.46PubMed CentralView ArticlePubMedGoogle Scholar
  26. Strandgaard S, Olesen J, Skinhoj E, Lassen NA: Autoregulation of brain circulation in severe arterial hypertension. Br Med J 1973, 1: 507–510. 10.1136/bmj.1.5852.507PubMed CentralView ArticlePubMedGoogle Scholar
  27. Slama M, Modeliar SS: Hypertension in the intensive care unit. Curr Opin Cardiol 2006, 21: 279–287. 10.1097/01.hco.0000231396.56738.d8View ArticlePubMedGoogle Scholar
  28. Marik PE, Varon J: Perioperative hypertension: a review of current and emerging therapeutic agents. J Clin Anesth 2009, 21: 220–229. 10.1016/j.jclinane.2008.09.003View ArticlePubMedGoogle Scholar
  29. Duncker DJ, Bache RJ: Regulation of coronary blood flow during exercise. Physiol Rev 2008, 88: 1009–1086. 10.1152/physrev.00045.2006View ArticlePubMedGoogle Scholar
  30. Cernaianu AC, Olah A, Cilley JH Jr, Gaprindashvili T, Gallucci JG, DelRossi AJ: Effect of sodium nitroprusside on paraplegia during cross-clamping of the thoracic aorta. Ann Thorac Surg 1993, 56: 1035–1037. 10.1016/0003-4975(95)90009-8View ArticlePubMedGoogle Scholar
  31. Powers DR, Papadakos PJ, Wallin JD: Parenteral hydralazine revisited. J Emerg Med 1998, 16: 191–196. 10.1016/S0736-4679(97)00287-4View ArticlePubMedGoogle Scholar
  32. Wei S, Kasuya Y, Yanagisawa M, Kimura S, Masaki T, Goto K: Studies on endothelium-dependent vasorelaxation by hydralazine in porcine coronary artery. Eur J Pharmacol 1997, 321: 307–314. 10.1016/S0014-2999(96)00972-7View ArticlePubMedGoogle Scholar
  33. Ludden TM, Shepherd AM, McNay JL, Lin MS: Hydralazine kinetics in hypertensive patients after intravenous administration. Clin Pharmacol Ther 1980, 28: 736–742. 10.1038/clpt.1980.229View ArticlePubMedGoogle Scholar
  34. Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P: Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ 2003, 327: 955–960. 10.1136/bmj.327.7421.955PubMed CentralView ArticlePubMedGoogle Scholar
  35. Magee LA, Abalos E, von Dadelszen P, Sibai B, Easterling T, Walkinshaw S: How to manage hypertension in pregnancy effectively. Br J Clin Pharmacol 2011, 72: 394–401. 10.1111/j.1365-2125.2011.04002.xPubMed CentralView ArticlePubMedGoogle Scholar
  36. Shusterman NH, Elliott WJ, White WB: Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function. Am J Med 1993, 95: 161–168. 10.1016/0002-9343(93)90256-OView ArticlePubMedGoogle Scholar
  37. Oparil S, Aronson S, Deeb GM, Epstein M, Levy JH, Luther RR, Prielipp R, Taylor A: Fenoldopam: a new parenteral antihypertensive: consensus roundtable on the management of perioperative hypertension and hypertensive crises. Am J Hypertens 1999, 12: 653–664. 10.1016/S0895-7061(99)00059-XView ArticlePubMedGoogle Scholar
  38. Murphy MB, Murray C, Shorten GD: Fenoldopam: a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N Engl J Med 2001, 345: 1548–1557. 10.1056/NEJMra010253View ArticlePubMedGoogle Scholar
  39. Hirschl MM, Binder M, Bur A, Herkner H, Brunner M, Mullner M, Sterz F, Laggner AN: Clinical evaluation of different doses of intravenous enalaprilat in patients with hypertensive crises. Arch Intern Med 1995, 155: 2217–2223. 10.1001/archinte.1995.00430200107014View ArticlePubMedGoogle Scholar
  40. Rhoney D, Peacock WF: Intravenous therapy for hypertensive emergencies, part 2. Am J Health Syst Pharm 2009, 66: 1448–1457. 10.2146/ajhp080348.p2View ArticlePubMedGoogle Scholar
  41. Narotam PK, Puri V, Roberts JM, Taylon C, Vora Y, Nathoo N: Management of hypertensive emergencies in acute brain disease: evaluation of the treatment effects of intravenous nicardipine on cerebral oxygenation. J Neurosurg 2008, 109: 1065–1074. 10.3171/JNS.2008.109.12.1065View ArticlePubMedGoogle Scholar
  42. Varon J, Marik PE: Perioperative hypertension management. Vasc Health Risk Manag 2008, 4: 615–627.PubMed CentralPubMedGoogle Scholar
  43. Curran MP, Robinson DM, Keating GM: Intravenous nicardipine: its use in the short-term treatment of hypertension and various other indications. Drugs 2006, 66: 1755–1782. 10.2165/00003495-200666130-00010View ArticlePubMedGoogle Scholar
  44. Peacock WF, Varon J, Baumann BM, Borczuk P, Cannon CM, Chandra A, Cline DM, Diercks D, Hiestand B, Hsu A, Jois-Bilowich P, Kaminski B, Levy P, Nowak RM, Schrock JW: CLUE: a randomized comparative effectiveness trial of IV nicardipine versus labetalol use in the emergency department. Crit Care 2011, 15: R157. 10.1186/cc10289PubMed CentralView ArticlePubMedGoogle Scholar
  45. Cannon CM, Levy P, Baumann BM, Borczuk P, Chandra A, Cline DM, Diercks DB, Hiestand B, Hsu A, Jois P, Kaminski B, Nowak RM, Schrock JW, Varon J, Peacock WF: Intravenous nicardipine and labetalol use in hypertensive patients with signs or symptoms suggestive of end-organ damage in the emergency department: a subgroup analysis of the CLUE trial. BMJ Open 2013, 3: e002338. 10.1136/bmjopen-2012-002338PubMed CentralView ArticlePubMedGoogle Scholar
  46. Malesker MA, Hilleman DE: Intravenous labetalol compared with intravenous nicardipine in the management of hypertension in critically ill patients. J Crit Care 2012, 27: 528. e7–14View ArticlePubMedGoogle Scholar
  47. Deeks ED, Keating GM, Keam SJ: Clevidipine: a review of its use in the management of acute hypertension. Am J Cardiovasc Drugs 2009, 9: 117–134. 10.1007/BF03256583View ArticlePubMedGoogle Scholar
  48. Awad AS, Goldberg ME: Role of clevidipine butyrate in the treatment of acute hypertension in the critical care setting: a review. Vasc Health Risk Manag 2010, 6: 457–464.PubMed CentralPubMedGoogle Scholar
  49. Nguyen HM, Ma K, Pham DQ: Clevidipine for the treatment of severe hypertension in adults. Clin Ther 2010, 32: 11–23. 10.1016/j.clinthera.2010.01.025View ArticlePubMedGoogle Scholar
  50. Aronson S, Dyke CM, Stierer KA, Levy JH, Cheung AT, Lumb PD, Kereiakes DJ, Newman MF: The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients. Anesth Analg 2008, 107: 1110–1121. 10.1213/ane.0b013e31818240dbView ArticlePubMedGoogle Scholar
  51. Peacock F, Varon J, Ebrahimi R, Dunbar L, Pollack CV Jr: Clevidipine for severe hypertension in acute heart failure: a VELOCITY trial analysis. Congest Heart Fail 2010, 16: 55–59. 10.1111/j.1751-7133.2009.00133.xView ArticlePubMedGoogle Scholar
  52. Peacock WF, Varon J, Ebrahimi R, Dunbar L, Pollack CV Jr: Clevidipine for severe hypertension in patients with renal dysfunction: a VELOCITY trial analysis. Blood Press Suppl 2011, 1: 20–25.View ArticleGoogle Scholar
  53. Pedersen ME, Cockcroft JR: The latest generation of beta-blockers: new pharmacologic properties. Curr Hypertens Rep 2006, 8: 279–286. 10.1007/s11906-006-0065-0View ArticlePubMedGoogle Scholar
  54. Che Q, Schreiber MJ Jr, Rafey MA: Beta-blockers for hypertension: are they going out of style? Cleve Clin J Med 2009, 76: 533–542. 10.3949/ccjm.76a.09030View ArticlePubMedGoogle Scholar
  55. Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Mbewu A, Opie LH: Beta-blockers for hypertension. Cochrane Database Syst Rev 2012., 11: CD002003Google Scholar
  56. Varon J: Treatment of acute severe hypertension: current and newer agents. Drugs 2008, 68: 283–297. 10.2165/00003495-200868030-00003View ArticlePubMedGoogle Scholar
  57. Chrysant SG, Chrysant GS, Dimas B: Current and future status of beta-blockers in the treatment of hypertension. Clin Cardiol 2008, 31: 249–252. 10.1002/clc.20249View ArticlePubMedGoogle Scholar
  58. Rodriguez MA, Kumar SK, De Caro M: Hypertensive crisis. Cardiol Rev 2010, 18: 102–107. 10.1097/CRD.0b013e3181c307b7View ArticlePubMedGoogle Scholar
  59. Gray RJ: Managing critically ill patients with esmolol, An ultra short-acting beta-adrenergic blocker. Chest 1988, 93: 398–403. 10.1378/chest.93.2.398View ArticlePubMedGoogle Scholar
  60. Pearce CJ, Wallin JD: Labetalol and other agents that block both alpha- and beta-adrenergic receptors. Cleve Clin J Med 1994, 61: 59–69. 10.3949/ccjm.61.1.59View ArticlePubMedGoogle Scholar
  61. McMillian WD, Trombley BJ, Charash WE, Christian RC: Phentolamine continuous infusion in a patient with pheochromocytoma. Am J Health Syst Pharm 2011, 68: 130–134. 10.2146/ajhp090619View ArticlePubMedGoogle Scholar
  62. Mazza A, Armigliato M, Zamboni S, Rempelou P, Rubello D, Pessina AC, Casiglia E: Endocrine arterial hypertension: therapeutic approach in clinical practice. Minerva Endocrinol 2008, 33: 297–312.PubMedGoogle Scholar
  63. Dooley M, Goa KL: Urapidil, A reappraisal of its use in the management of hypertension. Drugs 1998, 56: 929–955. 10.2165/00003495-199856050-00016View ArticlePubMedGoogle Scholar
  64. Jhund PS, McMurray JJ, Davie AP: The acute vascular effects of frusemide in heart failure. Br J Clin Pharmacol 2000, 50: 9–13.PubMed CentralView ArticlePubMedGoogle Scholar
  65. Tamagawa Y, Saino T, Matsuura M, Satoh Y: The effects of diuretics on intracellular Ca2+ dynamics of arteriole smooth muscles as revealed by laser confocal microscopy. Acta Histochem Cytochem 2009, 42: 121–128. 10.1267/ahc.09006PubMed CentralView ArticlePubMedGoogle Scholar
  66. Gregoretti C, Moglia B, Pelosi P, Navalesi P: Clonidine in perioperative medicine and intensive care unit: more than an anti-hypertensive drug. Curr Drug Targets 2009, 10: 799–814. 10.2174/138945009788982478View ArticlePubMedGoogle Scholar
  67. Prichard BN, Graham BR: I1 imidazoline agonists. General clinical pharmacology of imidazoline receptors: implications for the treatment of the elderly. Drugs Aging 2000, 17: 133–159. 10.2165/00002512-200017020-00005View ArticlePubMedGoogle Scholar
  68. Jamadarkhana S, Gopal S: Clonidine in adults as a sedative agent in the intensive care unit. J Anaesthesiol Clin Pharmacol 2010, 26: 439–445.PubMed CentralPubMedGoogle Scholar
  69. Cline JC, Connelly J: Intravenous clonidine for hypertensive emergencies. Am J Health Syst Pharm 1999, 56: 572–574.PubMedGoogle Scholar
  70. Farag E, Chahlavi A, Argalious M, Ebrahim Z, Hill R, Bourdakos D, Woo H: Using dexmedetomidine to manage patients with cocaine and opioid withdrawal, who are undergoing cerebral angioplasty for cerebral vasospasm. Anesth Analg 2006, 103: 1618–1620.View ArticlePubMedGoogle Scholar
  71. Khan IA, Nair CK: Clinical, diagnostic, and management perspectives of aortic dissection. Chest 2002, 122: 311–328. 10.1378/chest.122.1.311View ArticlePubMedGoogle Scholar


© Ribeiro Salgado et al.; licensee Springer. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.